Sotrovimab Or Xevudy Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The sotrovimab or xevudy market research report is one of a series of new reports that provides sotrovimab or xevudy market statistics, including the sotrovimab or xevudy industry's global market size, regional shares, competitors with a sotrovimab or xevudy market share, detailed sotrovimab or xevudy market segments, market trends and opportunities, and any further data you may need to thrive in the sotrovimab or xevudy industry. This sotrovimab or xevudy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to rising emergence of new COVID-19 variants, increasing focus on monoclonal antibody therapies, expanding healthcare access in developing regions, rising government support for pandemic preparedness, and growing telehealth services for treatment delivery. Major trends in the forecast period include advancements in vaccine manufacturing technologies, innovation in formulations, integration of telehealth, advancements in antibody production technologies, and advancements in antibody engineering.

The increasing prevalence of COVID-19 cases is expected to drive growth in the sotrovimab or Xevudy market. COVID-19, caused by the SARS-CoV-2 virus, spreads through respiratory droplets and can lead to symptoms ranging from mild fever to severe respiratory complications. While vaccines and hygiene practices play a role in prevention, the rise in cases is being influenced by factors such as new variants, waning immunity, the relaxation of restrictions, seasonal indoor gatherings, and uneven vaccine distribution. Sotrovimab helps manage high-risk COVID-19 patients by neutralizing the virus early, preventing severe outcomes such as hospitalization and death. For example, a report published in March 2023 by the Office for National Statistics in the UK estimated that 1.9 million people (about 2.9% of the population) were reporting COVID-19 symptoms, with many experiencing prolonged symptoms for over a year. As COVID-19 cases continue to rise, the demand for sotrovimab is expected to increase.

The growth of the sotrovimab or Xevudy market is also being driven by rising healthcare investments. Healthcare investments refer to the total spending on healthcare services, including medical treatments, medications, and hospital care, within a set timeframe. These investments are increasing due to factors such as an aging population, higher healthcare demands, advances in medical technology, and rising costs for services and medications. This increased investment in healthcare helps to support the development and availability of sotrovimab, enabling more research and development, expanding production, and improving access for high-risk patients through partnerships and distribution channels. For example, healthcare expenditure in the UK saw a 5.6% increase from 2022 to 2023, according to a May 2024 report by the Office for National Statistics. As healthcare investments continue to rise, they are expected to drive the growth of the sotrovimab market.

A significant trend in the sotrovimab or Xevudy market is the focus on strategic partnerships and efforts to expand production and improve access to the drug. These partnerships are critical for enhancing distribution and ensuring the drug reaches regions with the greatest need. For instance, in January 2022, GSK plc, a UK-based pharmaceutical company, collaborated with Vir Biotechnology Inc., a US-based biotech company, and reached an agreement with the United States government to purchase additional supplies of sotrovimab. This agreement was part of an ongoing effort to secure effective treatments as the pandemic evolves. Sotrovimab is designed for adults and adolescents at high risk of progressing to severe COVID-19, offering a critical treatment option for those who do not require oxygen supplementation. This strategic partnership reflects both companies' commitment to ensuring sotrovimab's availability in the face of emerging new virus variants.

The key companies operating in the sotrovimab or xevudy market are GSK plc and Vir Biotechnology Inc.

North America was the largest region in the sotrovimab or xevudy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in sotrovimab or xevudy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the sotrovimab or xevudy market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Sotrovimab (Xevudy) is a monoclonal antibody treatment developed to manage COVID-19. It specifically targets the SARS-CoV-2 spike protein, preventing the virus from entering and infecting human cells. Sotrovimab is used to treat mild-to-moderate COVID-19 in patients at high risk of progressing to severe illness, providing an effective therapeutic option during the early stages of infection.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary indication for sotrovimab (Xevudy) is early treatment of COVID-19 and post-exposure prophylaxis. Early treatment refers to the use of Sotrovimab in patients diagnosed with COVID-19 at the onset of symptoms, aiming to reduce symptom severity, prevent complications, and lower the risk of hospitalization, particularly for those at high risk of severe disease. It is distributed through various channels, including hospital pharmacies, retail pharmacies, and online platforms, and is used by pediatric, adult, and geriatric populations.

The sotrovimab or xevudy market consists of sales of pre-filled syringes and infusion kits. Values in this market are ‘factory gate’ values, representing the value of vaccines sold directly by manufacturers, either to governments, healthcare organizations, or distribution networks. This includes revenues from related services but excludes resales further along the supply chain or integration into other healthcare products.

The market value is defined as the revenues generated from the sale of vaccines and services within the market and geography, expressed in USD unless specified otherwise. These revenues represent consumption values based on vaccines used or distributed in a specific region, regardless of their place of production.

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.